Clinical Trials on Hemorrhage; Complicating Delivery, Coagulation Defect

Total 3585 results

Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Evaluating Inhibitor Specificity in Hemophilia A

Hemophilia A

Belgium, Italy, Spain, United States, United Kingdom, Germany, France
Green Cross Corporation

Completed

Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

Hemophilia A
CSL Behring
Parexel

Completed

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Hemophilia A

Bulgaria, Poland, Russian Federation, Macedonia, The Former Yugoslav Republic of
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Refacto For Pharmacovigilance

Hemophilia A

Germany, Austria
Bayer

Completed

BAY14-2222 Continuous Infusion in Surgeries

Hemophilia

Israel
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Hemophilia A

United States
Christian Medical College, Vellore, India

Unknown

Musculoskeletal Function in Hemophilia

Hemophilia

India, Argentina, Brazil, Egypt, Iran, Islamic Republic of, Singapore, South Africa, Thailand, Venezuela
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Effect of Epidural Analgesia on Labour, Neonatal and Maternal Outcomes.

Labor Pain | Regional Anesthesia Morbidity | Delivery Complication

Italy
Shanghai Belief-Delivery BioMed Co., Ltd
Shanghai MYGT Biopharmaceutical LLC

Recruiting

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Hemophilia A

China
East Kent Hospitals University NHS Foundation Trust

Not yet recruiting

Virtual Evaluations of Joint Health Using Wearable Sensors in Persons With Haemophilia (VESPA) (VESPA)

Haemophilia

United Kingdom
Ruijin Hospital

Recruiting

The Impact of Coagulation Disorders on the Diagnosis and Prognosis of Sepsis

Sepsis | Coagulation Disorder

China
BioMarin Pharmaceutical

Enrolling by invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) (GENEr8-LTE)

Hemophilia A

United Kingdom, United States
Novo Nordisk A/S

Enrolling by invitation

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

Haemophilia A

Denmark
BioMarin Pharmaceutical

Completed

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg (GENEr8-2)

Hemophilia A

United States
Hospices Civils de Lyon

Unknown

TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia (HOPE)

Haemophilia A

France
Royal Free Hospital NHS Foundation Trust

Unknown

Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B (InPath)

Haemophilia

United Kingdom
Beijing Children's Hospital

Unknown

Pharmacokinetic (PK)Research on Chinese Children of Hemophilia (PK)

Pharmacokinetics

China
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Haemophilia A

Poland, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Beijing Children's Hospital

Unknown

A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children (CHIPS)

Haemophilia

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Epidemiology and Immunology of Hemophilia A Inhibitors

Hemophilia A | Blood Disease
CytoSorbents, Inc

Terminated

Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D) (STAR-D)

Blood Loss, Surgical | Blood Loss, Postoperative | Hemorrhage, Surgical | Hemorrhage Postoperative

United States
University of California, San Francisco

Completed

Two Methods of Diagnosing Preterm Labor

Preterm Labor | Preterm Delivery

United States
Sanpasitthiprasong Hospital

Completed

Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor

Preterm Delivery

Thailand
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Hemophilia A

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

Hemophilia A

China
Octapharma

Not yet recruiting

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Hemophilia A

Spain, France, Finland, Germany, Italy, Serbia
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Emotions in the Communication and Relationship Styles of Parents With Hemophilic Children.

Hemophilia A

Italy
GC Biopharma Corp

Recruiting

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

Hemophilia

Korea, Republic of
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Christian Medical College, Vellore, India
Dr. H. Trent Spencer, Professor, Emory University of Medicine, Atlanta Ga...

Recruiting

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Hemophilia A

India
ASC Therapeutics

Recruiting

ASC618 Gene Therapy in Hemophilia A Patients

Hemophilia A

United States
Expression Therapeutics, LLC

Not yet recruiting

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Hemophilia A
University College, London
Medical Research Council

Recruiting

Gene Therapy for Haemophilia A. (GO-8)

Hemophilia A

United States, United Kingdom
Karolinska Institutet

Recruiting

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors

Hemophilia

Sweden
Pfizer

Active, not recruiting

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Hemophilia A

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)

Hemophilia A

Czechia, Switzerland, Denmark, Canada, Australia, Austria, France, United Kingdom, Italy, Sweden, Belgium, Brazil, China, Colombia, Greece, Hungary, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Bayer

Completed

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Hemophilia A

China
Baxalta now part of Shire

Active, not recruiting

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Hemophilia A

Spain, Thailand, Hungary, Taiwan, Korea, Republic of, Czechia, Germany, Sweden, Italy, Croatia, United States, Bulgaria, Netherlands
Bioverativ, a Sanofi company

Completed

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (XTEND-Kids)

Hemophilia A

Turkey, Australia, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Genzyme, a Sanofi Company

Active, not recruiting

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Hemophilia

Canada, Italy, Turkey, Spain, United States, India
Swedish Orphan Biovitrum
Cerner Enviza

Completed

Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination (A-MOVE)

Hemophilia A

France
Spark Therapeutics

Active, not recruiting

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Hemophilia A

United States, Canada, Australia
Emory University
Genentech, Inc.

Withdrawn

Emicizumab PUPs and Nuwiq ITI Study

Hemophilia A

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Novikang Medical Technology Co., LTD

Completed

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Hemophilia

China
Takeda
Takeda

Completed

ADYNOVATE Drug Use-Results Survey

Hemophilia A

Japan

Clinical Trials on Hemorrhage; Complicating Delivery, Coagulation Defect

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations